ClinicalTrials.Veeva

Menu
K

Ki Health Partners, LLC | New England Institute for Clinical Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Galcanezumab
Lasmiditan
LY573144
SAR441344
Erenumab
Atogepant
Frexalimab
Irsenontrine
CNP520
ABBV-950

Parent organization

This site is a part of Ki Health Partners, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 40 total trials
Locations recently updated

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling
Migraine
Drug: Erenumab Dose 3
Drug: Erenumab Dose 1

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Active, not recruiting
Migraine
Drug: Erenumab Dose 2
Drug: Erenumab Dose 3

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral do...

Enrolling
Multiple Sclerosis
Drug: Activated charcoal
Drug: Cholestyramine

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...

Enrolling
Multiple Sclerosis
Drug: Frexalimab
Drug: Placebo

Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the tre...

Active, not recruiting
Spasticity
Drug: Phase 2; Low Dose MYOBLOC
Drug: Phase 3; Placebo

Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the tre...

Active, not recruiting
Cerebrovascular Accident
Traumatic Brain Injury
Drug: Phase 3; MYOBLOC
Drug: Phase 2; Placebo

Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tas...

Active, not recruiting
Upper Limb Essential Tremor (UL ET)
Drug: Placebo for BOTOX
Biological: BOTOX

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling
Migraine
Drug: Placebo-Matching Ubrogepant
Drug: Ubrogepant

Trial sponsors

Lilly logo
AbbVie logo
Allergan logo
Amgen logo
K
Sanofi logo
Supernus Pharmaceuticals logo
A
A
Eisai logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems